Success Story: Senior Product Development Scientist from India Achieves EB1A Approval Despite Receiving NOID
Client’s Testimonial:
“Thanks a lot for taking care of my case. I am immensely happy and satisfied with your work.”
On December 5th, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for a Senior Product Development Scientist in the Field of Pharmaceutical Sciences (Approval Notice).
General Field: Pharmaceutical Sciences
Position at the Time of Case Filing: Senior Product Development Scientist
Country of Origin: India
State of Residence at the Time of Filing: Florida
Approval Notice Date: December 5th, 2025
Processing Time: 8 months 25 days
Case Summary:
“Therefore, [The Client] is clearly a leader in developing abuse-resistant pharmaceutical solutions that meet critical healthcare needs in the United States.“
This statement from an expert letter exemplifies the caliber of achievement our firm successfully presented in an EB-1A petition for a senior product development scientist from India specializing in pharmaceutical sciences. Holding a Ph.D. in Pharmaceutical Sciences, the client has established themselves as a leading expert in the field.
The case presented significant procedural complexity. After filing, USCIS issued a Notice of Intent to Deny (NOID). Our team immediately mobilized to prepare a comprehensive response that strategically reframed the evidence and strengthened the narrative of extraordinary ability. The petition was approved after 8 months and 25 days with our assistance.
We demonstrated that the client’s research in developing novel abuse-deterrent opioid formulations using 3D printing technology directly addresses critical national priorities, particularly the ongoing opioid crisis and FDA objectives for pharmaceutical safety. Our petition emphasized how this work fundamentally transforms both patient safety and public health protection.
To establish the client’s position at the very top of the field, we highlighted compelling objective evidence:
- 11 peer-reviewed journal articles (3 first-authored) in prestigious venues
- 766 citations
- Citations from researchers in 58 countries
- 37 peer reviews for distinguished journals
- 4 expert recommendation letters from internationally recognized scholars who had relied upon the client’s work in their own research.
We are honored to have supported this extraordinary researcher and extend our sincere best wishes for continued success in advancing pharmaceutical innovation and public health in the United States.